- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease (CD) Moderate to severe ulcerative colitis (UC) Severe active juvenile idiopathic arthritis (JIA) Complex refractory fistulising Crohn disease (CD) Severe active rheumatoid arthritis (RA) Severe psoriatic arthritis (PsA) Ankylosing spondylitis (AS) Severe chronic plaque psoriasis (CPP) Moderate to severe hidradenitis suppurativa (HS)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 396KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 66KB)
Adalimumab – July 2024
Adalimumab; Injection 20 mg in 0.2 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled syringe, Injection 40 mg in 0.4 mL pre-filled pen, Injection 80 mg 0.8 mL pre-filled syringe, Injection 80 mg in 0.8 mL pre-filled pen; Hyrimoz®
Last updated
30 May 2025
